National Major Scientific and Technological Special Projects for Significant New Drug Development
After 14-year development, the long-acting interferon drug product developed by Amoytop Biotech, Pegbing (Mipeginterferon alfa-2b), a national class-1 new drug, was approved in China in 2016. Pegbing is the first 40kD Y-shape branded PEG-modified interferon alfa-2b injection in the world. With a special structure under complete patent protection, it has broken the monopoly of foreign products in treatment of viral hepatitis, and was awarded with “2016 Top 10 China Medicinal Biotech Progress” by China Medicinal Biotechnology Association.
Recently, with the idea of “clinical cure” in chronic hepatitis B treatment field gradually recognized by hepatitis specialists and clinicians, Amoytop Biotech has supported and conducted a series of research projects aiming to improve CHB clinical cure level, including CHB clinical cure projects listed in the National Major Scientific and Technological Special Projects during the “13th Five-year Plan” period, exploratory researches on the application and optimization of chronic hepatitis B clinical cure, and relevant confirmatory clinical trials. Through continuous exploration and accumulation, Amoytop Biotech is devoted to being the leader in the field of CHB clinical cure based on pegylated interferon alfa-2b.
?
"Specialized in R&D and production of recombinant protein drugs, committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy"
Company Culture
Vision
To be a Leading International Biopharmaceutical Company in China
Mission
Devoted to Constant Innovation in Biopharmaceutical Field for a Better and Healthier Life for Human
Core Value
Responsibility丨Fairness丨Performance丨Win-Win
Milestones
2025
2023
2020
2016
2014
2012
2011
2010
2008
2005
2004
2002
1999
1997
1996
2025
Pegpesen ?（Pegsomatropin Injection）Launched，National Class 1 new drug.
2023
Pegneugen ? (Pegfilgrastim) Launched, National Class 1 New Drug
2020
Listed on SSE STAR Market (Sci-tech innovation board, Shanghai Stock Exchange), the first biomedical stock from Fujian Province
2016
Launched PEGBING? (Peginterferon alfa-2b), a national class 1 new drug
2014
Approved as “National Innovation Team in Priority Fields” by Ministry of Science and Technology
2012
Approved as "Key High-Tech Enterprises of National Torch Program”
2011
Approved as“National-Local Joint Research Center”
2010
Awarded“National Innovation-Oriented Enterprise”
2008
Established postdoctoral research station
2005
Launched TOPMEGA? (rHuIL-11)
2004
Undertook the Demonstration Project of Industrialization and Internationalization of Genetically Engineered Protein Drugs for National Development and Reform Committee, China
2002
Founded wholly-owned research institute,“Xiamen Biosteed Gene Transformation Tech. Co. ,Ltd.”
1999
Launched TOPNEUTER? (rHuG-CSF)
1997
Launched TOPLEUCON? (rHuGM-CSF), the first China-made GM-CSF
1996
Founded Amoytop Biotech
Awards and Honors
Social Responsibility
???????Great ships require deep waters; swift horses cover great distances. “Realizing the value of technology and knowledge by transforming them into products and services to benefit patients” is the initial mission and intention insisted on by Amoytop Biotech. As a pharmaceutical enterprise, promoting the development of the biomedical industry and providing a healthier life for more patients are the main social responsibility of Amoytop Biotech.
Facebook
Twitter
LinkedIn
Instagram
WELCOME
Specialized in R&D and production of recombinant protein drugs, and committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy etc..
